Ozmosi | F16IL2 Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

F16IL2

Alternative Names: F16IL2, F16-IL2
Clinical Status: Inactive
Latest Update: 2024-01-01
Latest Update Note: PubMed Publication

Product Description

An immunocytokine of the human monoclonal antibody fragment F16 (scFv) against the extra-domain A1 of tenascin-C fused, via a short 5-amino acid linker, to a recombinant form of the human cytokine interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. The monoclonal antibody portion of the F16-IL2 fusion protein binds to tumor cells expressing the tumor associated antigen (TAA) tenascin-C. In turn, the IL-2 moiety of the fusion protein stimulates natural killer (NK) cells, macrophages and neutrophils and induces T-cell antitumor cellular immune responses thereby selectively killing tenascin-C-expressing tumor cells. In addition, F16-IL2 may potentiate the cytotoxicity of other chemotherapeutic agents. Tenascin-C, a glycoprotein of the extracellular matrix, is expressed in many cancer cell types. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/f16-il2-fusion-protein)

Mechanisms of Action: NK Cells

Novel Mechanism: Yes

Modality: Fusion Protein

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Philogen S.p.A.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Non-Small-Cell Lung Cancer|Breast Cancer|Carcinoma, Merkel Cell|Melanoma

Phase 1: Acute Myeloid Leukemia

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT02957032

PH-F16IL2CYT-03/14

P1

Terminated

Acute Myeloid Leukemia

2023-09-29

9%

2023-10-11

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT03207191

PHIBI

P1

Completed

Acute Myeloid Leukemia

2020-03-26

2022-04-22

Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status

NCT05468294

Nivokin

P2

Unknown status

Non-Small-Cell Lung Cancer

2021-12-31

25%

2024-07-03

Primary Endpoints

NCT02054884

PH-F16IL2TAXO-03/12

P2

Terminated

Carcinoma, Merkel Cell

2016-12-31

2021-12-28

Primary Endpoints|Treatments

2012-004018-33

F16IL2 plus paclitaxel in metastatic Merkel cell carcinoma

P2

Terminated

Carcinoma, Merkel Cell

2015-04-24

2022-03-13

Treatments

NCT01134250

PH-F16IL2TAXO-05/07

P2

Completed

Non-Small-Cell Lung Cancer|Melanoma|Breast Cancer

2014-04-07

2022-04-16

Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status

NCT01131364

PH-F16IL2DOXO-04/07

P2

Terminated

Breast Cancer

2012-03-01

2024-11-27

Primary Endpoints|Treatments